<DOC>
	<DOC>NCT00430300</DOC>
	<brief_summary>Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage IIIII disease Patients must have a smoking history of at least 10 packyears Patients must have stable disease for at least 1 month prior to screening. More than 2 exacerbations of COPD in the preceding year History of a lower respiratory tract infection or significant disease instability during the month proceding screening or during the time between screen and randomization. History or presence of respiratory failure, cor pulmonale or right ventricular failure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Dry Powder for Inhalation</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Lung Function testing</keyword>
</DOC>